Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
|Videos|July 20, 2021
How prior authorization is affecting urology practices
Author(s)Urology Times staff
“[Prior authorization is] becoming a bigger and bigger problem for each practice,” says urologist Terrence Regan, MD.
Advertisement
In this video, Terrence Regan, MD, discusses how obtaining prior authorizations is affecting urology practices. Regan is a urologist with Advanced Urology Institute in Palm Coast, Florida and serves as chair of the American Association of Clinical Urologists’ Health Policy Committee.
Advertisement
Related to this article
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
William Huang, MD, discusses histotripsy for renal tumors, the #HOPE4KIDNEY trial, and the technology’s potential to preserve kidney function.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how workforce gaps may affect comprehensive infertility evaluations.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
5